Abstract: The present invention relates to CD4+ T cells, more specifically cytolytic or cytotoxic CD4+ T-cells and methods of obtaining and identifying them.
Abstract: [PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth. [MEANS] A monoclonal antibody against a necrosis marker consisting the following amino acid sequence: (1) the amino acid sequence of any of SEQ ID NOs: 1 to 3, or (2) an amino acid sequence having substitution, deletion and/or insertion of one or several amino acid residues in the amino acid sequence of (1) or sharing a homology of 90% or more with the amino acid sequence of (1), and showing the same function, activity or property as that of the amino acid sequence of (1) as a protein.
Abstract: An object of the present invention is to provide a monoclonal antibody binding to human XCR1, wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th, 11th, 12th, 13th, 14th, 16th, 17th, 22nd, 23rd, 176th, and 177th amino acids in the amino acid sequence of SEQ ID NO: 91.
Abstract: A method of treating a medical condition in which suppression of effector T cells is beneficial in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a CCL1 polypeptide, thereby treating the medical condition in the subject.
Type:
Grant
Filed:
May 5, 2011
Date of Patent:
May 31, 2016
Assignee:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Abstract: The present invention includes compositions and methods for targeting the LOX-1 receptor on immune cells and uses for the anti-LOX-1 antibodies.
Type:
Grant
Filed:
June 26, 2013
Date of Patent:
May 17, 2016
Assignee:
Baylor Research Institute
Inventors:
Jacques F. Banchereau, SangKon Oh, Gerard Zurawski, Sandra Zurawski, Dapeng Li
Abstract: The present invention is directed to a method of identifying CD4+ T cell antigens as well as to antigens which were identified by such a method. The present invention further is directed to the application of those identified antigens in medicine.
Type:
Grant
Filed:
April 24, 2006
Date of Patent:
May 17, 2016
Assignee:
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Inventors:
Josef Mautner, Uta Behrends, Slavoljub Milosevic
Abstract: Provided are compositions and methods for inhibiting cell growth. The cells that are targeted by the compositions and methods of the invention express an antigen, a mimotope of the antigen, or a CXCR4 chemokine receptor. The method entails administering to an individual a polynucleotide encoding an immunoglobulin Fc and an antigen expressed by the cells or a mimotope of the antigen. The method also involves administering to the individual a composition which contains a polynucleotide encoding an immunoglobulin Fc and an antagonist peptide of a CXCR4 chemokine receptor expressed by the cells. Also provided are proteins encoded by the polynucleotides.
Abstract: Disclosed are compositions and methods for detecting cells or tissue comprising a peptide antigen presented in the context of an MHC or HLA complex. The invention has a wide range of applications including providing a highly sensitive method for detecting cancer cells.
Type:
Grant
Filed:
February 18, 2014
Date of Patent:
March 22, 2016
Assignee:
ALTOR BIOSCIENCE CORPORATION
Inventors:
Shari A. Price-Schiavi, Heather J. Belmont, Kimberlyn F. Card, Xiaoyun Zhu, Hing C. Wong
Abstract: A method of generating a CD4+FoxP3+ Treg cell, the method includes administering at least one complement antagonist to a naive CD4+ T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4+ T cell, induce TGF-?1 expression of the CD4+ T cell, and induce differentiation of the of the naive CD4+ T cell into a CD4+FoxP3+ Treg cell.
Type:
Grant
Filed:
November 4, 2010
Date of Patent:
March 22, 2016
Assignee:
Case Western Reserve University
Inventors:
M. Edward Medof, Feng Lin, Michael G. Strainic
Abstract: The present invention relates to a composition containing PIAS3 as an active ingredient for the prevention or treatment of cancer or immune disease. More specifically, the present invention relates to a composition containing the PIAS3 gene or an expressing protein thereof as an active ingredient for the prevention or treatment of cancer or immune disease, to an immunosuppressant composition, to a method for reducing or inhibiting undifferentiated T cells into Th17 cells using the PIAS3 gene or an expressing protein thereof, and to a method for activating regulatory T cells.
Type:
Grant
Filed:
October 29, 2010
Date of Patent:
March 15, 2016
Assignee:
CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
Abstract: The present invention encompasses methods, and kits for the isolation and expansion of T regulatory cells having the CD45RA+ phenotype, including such cells from human umbilical cord blood.
Type:
Grant
Filed:
September 14, 2005
Date of Patent:
March 1, 2016
Assignee:
The Trustees of the University of Pennsylvania
Abstract: The present invention provides TCRs having high affinity. The TCR binds to SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 with a KD of less than or equal to 1 ?M and/or an off-rate (koff) of 1×10?3 S?1 or slower using Surface Plasmon Resonance. The TCRs are non-native, isolated or recombinant. The TCRs are useful, either alone, or with a therapeutic agent, for targeting HIV infected cells that present the SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 complex.
Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an allograft antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or treatment of allograft rejection and in the manufacture of medicaments therefore.
Abstract: The invention provides compositions and methods of treating various conditions, including tumors, with compositions comprising dendritic cells expressing exogenous chemokines.
Type:
Grant
Filed:
November 16, 2010
Date of Patent:
January 12, 2016
Assignee:
H. Lee Moffitt Cancer Center and Research Institute, Inc.
Abstract: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.
Type:
Grant
Filed:
June 19, 2009
Date of Patent:
January 5, 2016
Assignees:
The Trustees of the University of Pennsylvania, Regents of the University of Minnesota
Inventors:
James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
Abstract: The present invention relates to methods for isolating human forkhead box P3 (Foxp3+) CD4+ regulatory T cells (herein referred to a Foxp3+ Treg cells) from a sample containing (i) peripheral blood mononuclear cells (PBMCs), (ii) a lymphocyte containing fluid, or (iii) a lymphocyte containing tissue, a kit for isolating human Foxp3+ Treg cells, and the use of anti-CD49d antibody for the isolation of human Foxp3+ Treg cells.
Abstract: The invention relates to the regulation of the immune system, and in particular to the finding that the CLEC9a molecule is a marker for dendritic cells which are capable of cross-presenting extracellular antigens via the MHC class I pathway. This makes them particularly suitable for generation of cytotoxic T lymphocyte responses. Materials and methods are provided both for the induction of immune responses against target antigens, and for the inhibition or suppression of undesirable immune responses in which these cells are involved.
Type:
Grant
Filed:
October 9, 2013
Date of Patent:
December 8, 2015
Assignee:
Cancer Research Technology Limited
Inventors:
David Sancho-Madrid, Oliver Schulz, Neil Charles Rogers, Caetano Reis e Sousa, Olivier Pierre Joffre, Daniel Pennington
Abstract: The present invention encompasses methods, and kits for the isolation and expansion of T regulatory cells having the CD45RA+ phenotype, including such cells from human umbilical cord blood.
Type:
Grant
Filed:
July 9, 2012
Date of Patent:
November 17, 2015
Assignee:
The Trustees of the University of Pennsylvania
Abstract: A formulation and method for cultivating dendritic killer cells is disclosed in the present invention. The formulation comprises an effective amount of at least one cytokine and the abovementioned cytokine is IL-15. Furthermore, the method for cultivating dendritic killer cells at least comprises the following steps. A peripheral blood mononuclear cell population is obtained from human blood at first. Effective amounts of the cytokines in the formulation mentioned above are then added into the peripheral blood mononuclear cell population and the abovementioned peripheral blood mononuclear cell population is placed for a first appropriate period.